Cross Staff Investments’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.76M Hold
2,300
1.55% 15
2026
Q1
$2.12M Sell
2,300
-225
-9% -$228K 1.07% 16
2025
Q4
$2.71M Hold
2,525
1.49% 13
2025
Q3
$1.93M Sell
2,525
-15
-0.6% -$11.2K 1.35% 18
2025
Q2
$1.98M Hold
2,540
1.47% 18
2025
Q1
$2.1M Sell
2,540
-15
-0.6% -$12.5K 1.58% 14
2024
Q4
$1.97M Hold
2,555
1.37% 16
2024
Q3
$2.26M Buy
2,555
+15
+0.6% +$13.5K 1.75% 12
2024
Q2
$2.3M Hold
2,540
1.92% 9
2024
Q1
$1.98M Sell
2,540
-20
-0.8% -$14.2K 1.66% 12
2023
Q4
$1.49M Hold
2,560
1.32% 17
2023
Q3
$1.38M Hold
2,560
1.35% 16
2023
Q2
$1.2M Sell
2,560
-40
-2% -$16.8K 1.1% 22
2023
Q1
$893K Hold
2,600
0.88% 30
2022
Q4
$951K Buy
2,600
+500
+24% +$177K 1% 27
2022
Q3
$679K Hold
2,100
0.76% 35
2022
Q2
$681K Hold
2,100
0.75% 38
2022
Q1
$601K Hold
2,100
0.56% 52
2021
Q4
$580K Buy
+2,100
New +$532K 0.52% 56

Other funds holding LLY

Cross Staff Investments's LLY Position: Q2 2026 in Review

Cross Staff Investments held its Eli Lilly (LLY) position steady in Q2 2026 at 2,300 shares worth $2.76M. The position accounts for 1.55% of the portfolio, ranked #15.

Cross Staff Investments first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 2,247 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Cross Staff Investments held 2,300 shares of Eli Lilly worth $2.76M as of Q2 2026.
  • Cross Staff Investments left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 1.55% of Cross Staff Investments's portfolio in Q2 2026, its #15 holding.
  • Cross Staff Investments first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 2,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Cross Staff Investments's 13F filing for Q2 2026, filed 22 Jul 2026.